Minimally invasive hyperthermic intraperitoneal chemotherapy at the time of interval cytoreductive surgery for ovarian cancer: a case report

Ovarian cancer is the second most prevalent gynecologic cancer and the leading cause of death of all gynecologic malignancies. At the time of diagnosis, most patients have advanced-stage disease and neoadjuvant chemotherapy may be used in these patients to increase the chance of optimal cytoreductive surgery (CRS). Hyperthermic intraperitoneal chemotherapy (HIPEC) at the time of interval CRS has been shown to improve both recurrence free and overall survival in eligible patients. We present a case of a patient with a BMI of 54 who underwent a minimally invasive interval cytoreduction followed by HIPEC. This case demonstrates that minimally invasive HIPEC using standard equipment is safe, feasible, and cost effective.